About Generation Bio Co.
https://generationbio.comGeneration Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology.
CEO
Yalonda Howze
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-07-22 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Canaccord Genuity
Buy
Needham
Buy
Wedbush
Outperform
Citizens Capital Markets
Market Perform
Jefferies
Hold
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:3.29M
Value:$18.61M
ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC
Shares:827.95K
Value:$4.68M
MARSHALL WACE NORTH AMERICA L.P.
Shares:448.79K
Value:$2.54M
Summary
Showing Top 3 of 16
About Generation Bio Co.
https://generationbio.comGeneration Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.59M ▲ | $21.69M ▼ | $-5.52M ▲ | -346.3% ▲ | $-0.82 ▲ | $-4.12M ▲ |
| Q2-2025 | $765K ▼ | $23.68M ▼ | $-20.92M ▼ | -2.74K% ▼ | $-3.12 ▼ | $-21.27M ▼ |
| Q1-2025 | $8.72M ▲ | $25.33M ▼ | $-14.8M ▲ | -169.69% ▲ | $-2.21 ▲ | $-14.33M ▲ |
| Q4-2024 | $4.19M ▼ | $27.75M ▲ | $-21.38M ▼ | -510.55% ▼ | $-3.2 ▼ | $-18.79M ▼ |
| Q3-2024 | $7.55M | $25.44M | $-15.31M | -202.71% | $-2.29 | $-15.54M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $89.62M ▼ | $121.9M ▼ | $71.34M ▼ | $50.56M ▼ |
| Q2-2025 | $141.36M ▼ | $179.43M ▼ | $125.33M ▼ | $54.1M ▼ |
| Q1-2025 | $157.56M ▼ | $201.35M ▼ | $128.02M ▼ | $73.33M ▼ |
| Q4-2024 | $185.22M ▲ | $231.2M ▼ | $144.99M ▲ | $86.2M ▼ |
| Q3-2024 | $184.77M | $248.78M | $144.34M | $104.44M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-5.52M ▲ | $-52.68M ▼ | $25.53M ▲ | $-2K ▼ | $-27.15M ▼ | $-52.68M ▼ |
| Q2-2025 | $-20.92M ▼ | $-16.83M ▲ | $14.95M ▲ | $80K ▲ | $-1.8M ▲ | $-17.29M ▲ |
| Q1-2025 | $-14.8M ▲ | $-28.36M ▼ | $2.96M ▼ | $-7K ▼ | $-25.41M ▼ | $-28.61M ▼ |
| Q4-2024 | $-21.38M ▼ | $-15.78M ▲ | $70.28M ▲ | $144K ▲ | $54.64M ▲ | $-16.16M ▲ |
| Q3-2024 | $-15.31M | $-19.55M | $12.71M | $-3K | $-6.84M | $-19.64M |
CEO
Yalonda Howze
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-07-22 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Canaccord Genuity
Buy
Needham
Buy
Wedbush
Outperform
Citizens Capital Markets
Market Perform
Jefferies
Hold
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:3.29M
Value:$18.61M
ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC
Shares:827.95K
Value:$4.68M
MARSHALL WACE NORTH AMERICA L.P.
Shares:448.79K
Value:$2.54M
Summary
Showing Top 3 of 16